EUVIMEDEUVIMED entdecken
Crossref

Variable Duration Trial as an Alternative Design for Continuous Endpoints

Jitendra Ganju iD, Julie Guoguang Ma

Pharmaceutical Statistics · 2024

DOI: 10.1002/pst.2418 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2024. Verfasst von Jitendra Ganju und 1 weiteren Autor:innen. Beteiligte Einrichtung: Ganju Clinical Trials, LLC, San Francisco, California, USA. Hauptthemen laut MEDLINE: Research Design, Endpoint Determination, Clinical Trials as Topic. Die Arbeit nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials with continuous primary endpoints typically measure outcomes at baseline, at a fixed timepoint (denoted T min ), and at intermediate timepoints. The analysis is commonly performed using the mixed model repeated measures method. It is sometimes expected that the effect size will be larger with follow‐up longer than T min . But extending the follow‐up for all patients delays trial completion. We propose an alternative trial design and analysis method that potentially increases statistical power without extending the trial duration or increasing the sample size. We propose following the last enrolled patient until T min , with earlier enrollees having variable follow‐up durations up to a maximum of T max . The sample size at T max will be smaller than at T min , and due to staggered enrollment, data missing at T max will be missing completely at random. For analysis, we propose an alpha‐adjusted procedure based on the smaller of the p values at T min and T max , termed . This approach can provide the highest power when the powers at T min and T max are similar. If the power at T min and T max differ significantly, the power of is modestly reduced compared with the larger of the two powers. Rare disease trials, due to the limited size of the patient population, may benefit the most with this design.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignEndpoint DeterminationClinical Trials as TopicHumansSample SizeTime FactorsModels, StatisticalData Interpretation, Statistical

Stichwörter der Autor:innen

continuous endpointsminimum p valuepowervariable duration trials

Autor:innen und Institutionen

  • Ganju Clinical Trials, LLC, San Francisco, California, USA.
  • RemeGen Co., Ltd, Yantai, China.

ORCID-Profile: Jitendra Ganju

Zitieren

APA

Ganju, J., & Ma, J. G. (2024). Variable Duration Trial as an Alternative Design for Continuous Endpoints. Pharmaceutical Statistics. https://doi.org/10.1002/pst.2418

Vancouver

Ganju J, Ma JG. Variable Duration Trial as an Alternative Design for Continuous Endpoints. Pharmaceutical Statistics. 2024. doi:10.1002/pst.2418

BibTeX
@article{Ganju2024,
  author = {Ganju, Jitendra and Ma, Julie Guoguang},
  title = {Variable Duration Trial as an Alternative Design for Continuous Endpoints},
  journal = {Pharmaceutical Statistics},
  year = {2024},
  doi = {10.1002/pst.2418}
}
Kostenlos starten →